Treatment Considerations in MDS from ASCO/EHA 2022

 

Penn Medicine Abramson Cancer Center
S

Highlights in the Prognostication of MDS This Year

By Penn Medicine Abramson Cancer Center FEATURING Shannon McCurdy
By Penn Medicine Abramson Cancer Center FEATURING Shannon McCurdy
34 views
May 4, 2022
0 Comments
Login to view comments. Click here to Login
Treatment Considerations in MDS from ASCO/EHA 2022
24:29
MDS Foundation

Immunotherapy Strategies in MDS

Feat. S. Gill
24:49
MDS Foundation

The Evolving Use of Immune Checkpoint Blockade in Management of MDS

Feat. A. Zeidan
22:43
Penn Medicine Abramson Cancer Center

Highlights in the Prognostication of MDS This Year

Feat. S. McCurdy
20:10
Rush University Medical Center

Novel Agents for MDS

Feat. S. Dinner
04:48
EHA 2022 Conference Coverage

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Hi…

Feat. D. Sallman
10:02
Gautham Borthakur

Anti-CD47 Therapy in MDS

15:31
Yale Cancer Center

The Importance of the TP53 Evaluation in the Management of HR-MDS

Feat. R. Shallis
09:58
Penn Medicine Abramson Cancer Center

EHA and ASCO 2022 Penn Medicine Updates on AML and MDS

Feat. K. Pratz
20:03
SOHO Italy 1st Clinical and Biological School of CAR-T

T, NK, and Macrophage-Based Therapies in AML

Feat. N. Daver
39:34
MDS Foundation

Making Heads and Tails of NGS Printouts and Their Role in MDS

Feat. B. Ebert
16:58
MDS Foundation

Mechanisms and Predictors of Drug Resistance in HR-MDS: Intolerance …

Feat. M. Sekeres
27:27
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 State of the Art Frontline Management of the HR-MDS

Feat. R. Komrokji
06:24
EHA 2022 Conference Coverage

EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magro…

Feat. D. Sallman
30
EHA 2022 Conference Coverage

Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clini…

Feat. D. Sallman
35:36
MDS Foundation

Optimizing Transfusion Support for Patients With MDS

Feat. Y. Lin